VRTX Quote, Financials, Valuation and Earnings

Biogen has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 10.87%. Vertex Pharmaceuticals's return on equity of -3.23% beat Biogen's return on equity of 10.33%.

Vertex Pharmaceuticals has a consensus price target of $500.32, signalling upside risk potential of 1.31%. On the other hand Biogen has an analysts' consensus of $190.50 which suggests that it could grow by 60.3%. Given that Biogen has higher upside potential than Vertex Pharmaceuticals, analysts believe Biogen is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.9B, which are larger than Biogen quarterly revenues of $2.5B. Vertex Pharmaceuticals's net income of $913M is higher than Biogen's net income of $266.7M. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.62x versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 19.72%. Vertex Pharmaceuticals's return on equity of -3.23% beat Gilead Sciences's return on equity of 32.29%.

Vertex Pharmaceuticals has a consensus price target of $500.32, signalling upside risk potential of 1.31%. On the other hand Gilead Sciences has an analysts' consensus of $113.75 which suggests that it could grow by 10.26%. Given that Gilead Sciences has higher upside potential than Vertex Pharmaceuticals, analysts believe Gilead Sciences is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.01% to investors and pays a quarterly dividend of $0.79 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Vertex Pharmaceuticals's net income of $913M is lower than Gilead Sciences's net income of $1.3B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Gilead Sciences's PE ratio is 21.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.62x versus 4.53x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of 32.59%. Vertex Pharmaceuticals's return on equity of -3.23% beat Eli Lilly and's return on equity of 80.24%.

Vertex Pharmaceuticals has a consensus price target of $500.32, signalling upside risk potential of 1.31%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 14.03%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.61% to investors and pays a quarterly dividend of $1.50 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals quarterly revenues are $2.9B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Vertex Pharmaceuticals's net income of $913M is lower than Eli Lilly and's net income of $4.4B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Eli Lilly and's PE ratio is 75.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.62x versus 17.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 31.35% compared to Vertex Pharmaceuticals's net margin of -117.16%. Vertex Pharmaceuticals's return on equity of -3.23% beat Moderna's return on equity of -29.09%.

Vertex Pharmaceuticals has a consensus price target of $500.32, signalling upside risk potential of 1.31%. On the other hand Moderna has an analysts' consensus of $49.96 which suggests that it could grow by 83.55%. Given that Moderna has higher upside potential than Vertex Pharmaceuticals, analysts believe Moderna is more attractive than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has a beta of 0.504, which suggesting that the stock is 49.617% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Vertex Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Vertex Pharmaceuticals quarterly revenues are $2.9B, which are larger than Moderna quarterly revenues of $956M. Vertex Pharmaceuticals's net income of $913M is higher than Moderna's net income of -$1.1B. Notably, Vertex Pharmaceuticals's price-to-earnings ratio is 26.10x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals is 11.62x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.